128 related articles for article (PubMed ID: 7197583)
1. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.
Pratt CB; Hayes A; Green AA; Evans WE; Senzer N; Howarth CB; Ransom JL; Crom W
Cancer Treat Rep; 1981; 65(11-12):1021-6. PubMed ID: 7197583
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cis-dichlorodiammineplatinum(II) in children with advanced malignant diseases: Southwest Oncology Group Studies.
Vietti TJ; Nitschke R; Starling KA; van Eys J
Cancer Treat Rep; 1979; 63(9-10):1611-4. PubMed ID: 291482
[TBL] [Abstract][Full Text] [Related]
3. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.
Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D
Cancer Treat Rep; 1981; 65(9-10):815-22. PubMed ID: 6944156
[TBL] [Abstract][Full Text] [Related]
4. [Effect of cis-platinum in neuroblastoma].
Nakadate H; Nishi M; Hattori T; Hatae Y; Takeda T
Gan To Kagaku Ryoho; 1985 Jan; 12(1):147-50. PubMed ID: 4038446
[TBL] [Abstract][Full Text] [Related]
5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
6. Clinical response and toxicity with cis-dichlorodiammineplatinum(II) in children.
Kamalakar P; Freeman AI; Higby DJ; Wallace HJ; Sinks LF
Cancer Treat Rep; 1977 Aug; 61(5):835-9. PubMed ID: 890692
[TBL] [Abstract][Full Text] [Related]
7. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of cisplatin in children with malignant solid tumors. Pediatric Cisplatin Study Group].
Suganuma Y; Ise T; Akiyama Y; Bessho F; Fukazawa K; Hirotsu T; Kitamura T; Koide A; Matsuyama K; Muchi H
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3083-90. PubMed ID: 3674893
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study.
Talley RW; O'Bryan RM; Gutterman JU; Brownlee RW; McCredie KB
Cancer Chemother Rep; 1973; 57(4):465-71. PubMed ID: 4762440
[No Abstract] [Full Text] [Related]
10. [Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial].
Hayat M; Bayssas M; Brulé G; Cappelaere P; Cattan A; Chauvergne J; Clavel B; Gouveia J; Guerrin J; Pommatau E; Muggia F; Mathé G
Nouv Presse Med; 1979 Mar; 8(15):1231-4. PubMed ID: 375187
[TBL] [Abstract][Full Text] [Related]
11. [Effects of cis-DDP in children with refractory malignant tumors].
Nakadate H; Kobayashi R; Nishi M; Hatae Y; Takeda T; Uchino J; Hirama T; Kobayashi H
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):598-603. PubMed ID: 3954383
[TBL] [Abstract][Full Text] [Related]
12. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
13. [Use of prolonged intravenous infusions of cisplatin in patients with malignant neoplasms].
Tiuliadin SA
Vopr Onkol; 1983; 29(12):40-4. PubMed ID: 6582683
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and cisplatin therapy in children with neuroblastoma resistant to conventional therapy: a Southwest Oncology Group Study.
Nitschke R; Starling K; Lui VK; Pullen J
Cancer Treat Rep; 1981; 65(11-12):1105-8. PubMed ID: 7028253
[TBL] [Abstract][Full Text] [Related]
16. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
19. Phase I study on bruceantin administered on a weekly schedule.
Liesmann J; Belt RJ; Haas CD; Hoogstraten B
Cancer Treat Rep; 1981; 65(9-10):883-5. PubMed ID: 7273023
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
